We propose that sequence-encoded structural distortion, rather than lesion chemistry alone, dictates lesion recognisability, binding pathway success, and ultimately mutational hotspot formation within KRAS in smoking-related lung cancers. The gene discussed is KRAS; the disease is lung cancer.